Perrigo Company plc (PRGO) - Q3 2024 10-Q Summary
Business Context and Reporting Period
Perrigo Company plc is a leading provider of over-the-counter (OTC) health and wellness solutions, operating primarily in North America and Europe. The company is organized into two reporting segments: Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). This report covers the quarterly period ended September 28, 2024. During the quarter, the company completed the sale of its HRA Pharma Rare Diseases Business and signed a definitive agreement to sell its Orion Laboratories Hospital & Specialty Business (completed November 1, 2024).
Key Financial Metrics
| Metric | Q3 2024 | Q3 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Net Sales ($ millions) | $1,087.5 | $1,123.8 | $3,235.1 | $3,498.7 |
| Gross Profit ($ millions) | $404.4 | $411.2 | $1,156.8 | $1,253.1 |
| Gross Margin (%) | 37.2% | 36.6% | 35.8% | 35.8% |
| Operating Income ($ millions) | $80.4 | $62.1 | $(1.3) | $167.5 |
| Net Income (Loss) ($ millions) | $(21.0) | $14.2 | $(127.3) | $19.6 |
| Diluted EPS ($) | $(0.15) | $0.10 | $(0.93) | $0.14 |
| Cash & Equivalents ($ millions) | $1,463.5 | $751.3 (Dec 2023) | N/A | N/A |
| Total Debt ($ millions) | $4,753.3 | $4,073.4 (Dec 2023) | N/A | N/A |
Material Changes vs. Prior Period
- Revenue Decline: Q3 net sales decreased 3.2% year-over-year, driven by lost distribution of lower-margin U.S. store brand products, lower sales in Oral Care and Pain & Sleep-Aids, and the divestiture of the Rare Diseases Business. YTD sales decreased 7.5%.
- Profitability Volatility: While Q3 operating income improved by 29.5% to $80.4 million due to expense reductions and pricing actions, YTD operating income turned negative ($(1.3) million) compared to $167.5 million in the prior year. This was primarily due to $98.1 million in restructuring charges, $50.3 million in impairment charges, and increased litigation provisions.
- Divestitures and Impairments: The company recorded a $5.8 million gain on the sale of the Rare Diseases Business. Conversely, it recognized $16.2 million in impairment charges related to the Hospital & Specialty Business held for sale and $22.1 million in goodwill impairment for the Rare Diseases Business prior to its sale.
- Debt Restructuring: In September 2024, the company issued $1.065 billion in new 2032 Notes (USD and Euro). Proceeds were used to prepay Term Loan B and redeem $700 million of 2026 Notes, resulting in a $5.1 million loss on extinguishment of debt.
Guidance, Outlook, and Risks
- Strategic Initiatives: The company is executing "Project Energize," a global efficiency program expected to deliver $140 million to $170 million in annualized pre-tax savings by 2026, with restructuring costs estimated between $140 million and $160 million. The "Supply Chain Reinvention Program" is also ongoing, with expected costs reduced to $100 million by 2025.
- Infant Formula: Following FDA warning letters and production pauses at the Wisconsin facility, the company has resumed production but expects 2024 results to be below 2023 levels due to remediation costs and unabsorbed overhead. Estimated cash costs for remediation in 2024 are $15 million to $20 million.
- Tax Outlook: Management projects an unusually high annual effective tax rate for 2024 due to inter-company IP sales, non-deductible expenses, and a partial valuation allowance in the U.S.
- Legal Contingencies: Significant litigation risks remain, including price-fixing lawsuits related to the former Rx business (MDL No. 2724), securities litigation (settled for $97 million in Q3), and product liability cases involving talcum powder and ranitidine. A $41.9 million accrual for litigation contingencies is recorded on the balance sheet.
- Geopolitical Risks: The company monitors the war in Ukraine and conflicts in the Middle East for potential supply chain disruptions and economic impacts.
Investor Verification Checklist
- Restructuring Execution: Verify the progress and cost realization of "Project Energize" and the "Supply Chain Reinvention Program" against the stated savings targets.
- Infant Formula Recovery: Monitor the timeline for full inventory replenishment and margin recovery in the U.S. Nutrition segment following the Wisconsin facility remediation.
- Debt Service Capacity: Assess the impact of the new 2032 Notes and the redemption of 2026 Notes on future interest expense and liquidity, particularly given the credit rating downgrades (S&P BB-, Fitch BB).
- Litigation Resolution: Track the status of the price-fixing MDL bellwether cases and the remaining opt-out securities litigation to evaluate potential future cash outflows beyond current accruals.
- Divestiture Proceeds: Confirm the final working capital adjustments and earn-out valuations for the Rare Diseases Business sale and the closing details of the Hospital & Specialty Business sale.